That said, there are limited investigations into their role in neurodegenerative disorders, with only a handful of studies focusing on CD1d changes in neurodegeneration (Iba et al., 2024; Muir et al., 2020; Parekh et al., 2013); these include using an anti-CD1d mAb to reduce the number of NKT cells in α-synuclein transgenic mice and elevated astrocyte CD1d expression in MS. This evidence concerns the gene CD1D and myeloid sarcoma.